Overall impact
B (65)

Commentary

Ceribell is a strong overall performer. With a 'B' rating of 64.7 for overall impact (73rd percentile compared to all companies), Ceribell ranks 107th out of 196 industry peers, behind ConTIPI, Restoration Robotics, Corindus Vascular Robotics and 103 others, and ahead of Axonics Modulation Technologies, LifeScan, Star Equity Holdings and 86 others. On top material causes for Ceribell's industry (Health Care Equipment & Supplies), Ceribell performs well in Child and Maternal Health (95.2 score), Child and Maternal Health (95.2), Access to Affordable Healthcare (91.3) and 9 other causes where it received an 'A' score and performs poorly in Sanitation Access (25.1 score), Free, Secure Flow of Information (21.4), Sanitation Access (25.1) and 2 other causes where it received a 'D' or 'F' score.
Impact
Cause CBLL
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2014
Employees
240
Sector
Health Care
Industry
Health Care Equipment & Supplies
Sub-industry
Health Care Equipment
SASB industry
Medical Equipment & Supplies
Headquarters
California, United States
Share classes
CBLL
Description
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.
Material causes
Ethos considers the following causes material for Ceribell, based on its industry sub-industry Health Care Equipment. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.